secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001641489-25-000032
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial
----------------------------------------------------------------------------

- Michael Tung appointed EVP and CFO effective May 19, 2025; base salary $450,000, target bonus 40%.
- Tung brings 20+ years finance experience; previously CFO at AdvanCell, VP at FibroGen.
- Company reinitiated screening in CATT1 Phase 3 trial for cadisegliatin, oral T1D adjunct to insulin.
- Employment agreement includes 45,000 stock option grant, 9-month severance, 9-month non-compete.
- No prior CFO departure disclosed; appointment comes at 'critical inflection point' per CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/0001641489-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/vtvt-20250519.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer